TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs

被引:13
|
作者
Reuss, Simone [1 ]
Sebestyen, Zsolt [2 ]
Heinz, Niels [3 ]
Loew, Rainer [4 ]
Baum, Christopher [3 ]
Debets, Reno [2 ]
Uckert, Wolfgang [1 ,5 ]
机构
[1] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany
[2] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Hannover Med Sch, Hannover, Germany
[4] Eufets GmbH, Idar Oberstein, Germany
[5] Humboldt Univ, Inst Biol, D-10099 Berlin, Germany
关键词
RECEPTOR GENE-THERAPY; ENHANCED ANTITUMOR-ACTIVITY; CANCER REGRESSION; SINGLE-CHAIN; LYMPHOCYTES; ALPHA; BETA; ANTIGEN; SPECIFICITY; RECOGNITION;
D O I
10.1002/eji.201343591
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TCR gene modified T cells for adoptive therapy simultaneously express the Tg TCR and the endogenous TCR, which might lead to mispaired TCRs with harmful unknown specificity and to a reduced function of TCR-Tg T cells. We generated dual TCR T cells in two settings in which either TCR was constitutively expressed by a retroviral promoter while the second TCR expression was regulable by a Tet-on system. Constitutively expressed TCR molecules were reduced on the cell surface depending on the induced TCR expression leading to strongly hampered function. Besides that, using fluorescence resonance energy transfer we detected mispaired TCR dimers and different pairing behaviors of individual TCR chains with a mutual influence on TCR chain expression. The loss of function and mispairing could not be avoided by changing the TCR expression level or by introduction of an additional cysteine bridge. However, in polyclonal T cells, optimized TCR formats (cysteineization, codon optimization) enhanced correct pairing and function. We conclude from our data that (i) the level of mispairing depends on the individual TCRs and is not reduced by increasing the level of one TCR, and (ii) modifications (cysteineization, codon optimization) improve correct pairing but do not completely exclude mispairing (cysteineization). © 2013 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 50 条
  • [41] Accelerating development and improving access to CAR- and TCR-engineered T cell therapy in Europe
    Luu, Maik
    Sanges, Carmen
    Hoen, Ninja
    Draper, Aleksandra
    Sheth, Sapna
    Wagers, Scott
    Negre, Helene
    Hudecek, Michael
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 412 - 412
  • [42] Generation of TCR-engineered reference cell samples to control T-cell assay performance
    Bidmon, Nicole
    Gouttefangeas, Cecile
    van der Burg, Sjoerd H.
    TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - CELLULAR METHODS, PT A, 2020, 631 : 195 - 221
  • [43] ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE
    Luu, M.
    Sanges, C.
    Hoen, N.
    Draper, A.
    Sheth, S.
    Wagers, S.
    Negre, H.
    Hudecek, M.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A37 - A37
  • [44] TCR engineered T cells for solid tumor immunotherapy
    Yikai Zhang
    Zhipeng Liu
    Wei Wei
    Yangqiu Li
    Experimental Hematology & Oncology, 11
  • [45] TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
    Nagarsheth, Nisha B.
    Norberg, Scott M.
    Sinkoe, Andrew L.
    Adhikary, Sabina
    Meyer, Thomas J.
    Lack, Justin B.
    Warner, Andrew C.
    Schweitzer, Colleen
    Doran, Stacey L.
    Korrapati, Soumya
    Stevanovic, Sanja
    Trimble, Cornelia L.
    Kanakry, Jennifer A.
    Bagheri, Mohammad Hadi
    Ferraro, Erin
    Astrow, Stephanie H.
    Bot, Adrian
    Faquin, William C.
    Stroncek, David
    Gkitsas, Nikolaos
    Highfill, Steven
    Hinrichs, Christian S.
    NATURE MEDICINE, 2021, 27 (03) : 419 - +
  • [46] Establishment of Automated Point-of-Care Manufacturing of ΔNPM1 TCR-Engineered T Cells for AML Therapy
    Ogusuku, Isabella Elias Yonezawa
    Agiro, Eva
    Herbel, Vera
    Brandes, Caroline
    Veld, Sabrina
    Hageman, Lois
    Griffioen, Marieke
    Schaser, Thomas
    de Groot, Rosa
    Lock, Dominik
    Johnston, Ian C. D.
    MOLECULAR THERAPY, 2024, 32 (04) : 153 - 154
  • [47] Early TCRα expression during T cell development for the generation of enhanced-affinity TCRs for TCR gene therapy.
    Schmitt, Thomas M.
    Greenberg, Philip D.
    Aggen, David H.
    Kranz, David
    Ochsenreither, Sebastian
    CANCER RESEARCH, 2013, 73
  • [48] ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE
    Luu, M.
    Carmen, S.
    Draper, A.
    Hoen, N.
    Sheth, S.
    Wagers, S.
    Negre, H.
    Hudecek, M.
    CYTOTHERAPY, 2022, 24 (05) : S130 - S130
  • [49] TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
    Nisha B. Nagarsheth
    Scott M. Norberg
    Andrew L. Sinkoe
    Sabina Adhikary
    Thomas J. Meyer
    Justin B. Lack
    Andrew C. Warner
    Colleen Schweitzer
    Stacey L. Doran
    Soumya Korrapati
    Sanja Stevanović
    Cornelia L. Trimble
    Jennifer A. Kanakry
    Mohammad Hadi Bagheri
    Erin Ferraro
    Stephanie H. Astrow
    Adrian Bot
    William C. Faquin
    David Stroncek
    Nikolaos Gkitsas
    Steven Highfill
    Christian S. Hinrichs
    Nature Medicine, 2021, 27 : 419 - 425
  • [50] Maintenance of TCR clonality in T cells expressing genes for two TCR heterodimers
    Sant'Angelo, DB
    Cresswell, P
    Janeway, CA
    Denzin, LK
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) : 6824 - 6829